イブリツモマブ　チウキセタン（遺伝子組換え）

イブリツモマブ　チウキセタン（遺伝子組換え） 化学特性,用途語,生産方法

• 使用

  Antineoplastic (monoclonal antibody) [Note—Yttrium-labeled ibritumomab tiuxetan is used for the treatment of non-Hodgkin’s B-cell lymphoma, coadministered with rituximab].

• 一般的な説明

  Ibritumomab (Zevalin kits to prepare In-111 Zevalin and Y-90 Zevalin, murine) is an MAb derived from an initial sensitizationwith CD20 antigen, expressed on the surface ofnormal and malignant B cells. The antibody is a murineIgG1 κ subtype, directed against CD20 antigen. It is producedin a CHO cell line. Ibritumomab is indicated for useas a multistage regimen to treat patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin lymphoma, including patients with rituximabrefractoryfollicular non-Hodgkin lymphoma.
  Ibritumomab tiuxetan binds specifically to CD20 antigen(human B-lymphocyte–restricted differentiation antigen).CD20 is expressed on pre-B and mature B lymphocytes andon more than 90% of B-cell non-Hodgkin lymphoma. Whenthe CDR of ibritumomab tiutuxan binds to the CD20 antigen,apoptosis is initiated. The tiutuxan chelate binds indium-111and yttrium-90 tightly. Beta emission induces cellular damageby forming free radicals in the target cells and neighboringcells. Tiutuxan is [N-[2-bis(carboxymethyl)amino]-3-(p-isothiocyanatophenyl)propyl]-[N-[2-bis(carboxymethyl)amino]2-(methyl)-ethyl]glycine.

イブリツモマブ　チウキセタン（遺伝子組換え） 生産企業

Global(9)Suppliers